Analyst Price Target is $48.03
▲ +56.20% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Tabula Rasa HealthCare in the last 3 months. The average price target is $48.03, with a high forecast of $55.00 and a low forecast of $40.00. The average price target represents a 56.20% upside from the last price of $30.75.
Current Consensus is
The current consensus among 8 contributing investment analysts is to hold stock in Tabula Rasa HealthCare. This rating has held steady since December 2020, when it changed from a Buy consensus rating.
Tabula Rasa Healthcare, Inc. is a healthcare technology company, which engages in the development of solutions designed for pharmacists, providers, and patients to optimize medication regimens. It operates through the following segments: CareVention HealthCare and MedWise HealthCare. The CareVention HealthCare segment provides services, PACE, which is a center for Medicare & Medicaid services, or CMS, sponsored program providing medical and social services. Its brands include CareKinesis, Capstone Risk Adjustment Services, PACElogic, TruChart, PeakTPA, PersonifilRx, and Pharmastar. The MedWise HealthCare segment provides Medication Therapy Management, or MTM, software and services for Medicare, Medicaid, and commercial health plans, and also provides a cloud-based patient engagement software and services. It offers cloud-based software and clinical pharmacist services through its brands, including MedWise, SinfoníaRx, RxCompanion, PrescribeWellness, and DoseMeRx. The company was founded by Calvin H. Knowlton, Orsula V. Knowlton, and Michael Greenhalgh in April 2009 and is headquartered in Moorestown, NJ.